MARKET

MTVA

MTVA

MetaVia Inc
NASDAQ
0.6899
-0.0200
-2.82%
Opening 11:51 07/15 EDT
OPEN
0.7050
PREV CLOSE
0.7099
HIGH
0.7080
LOW
0.6810
VOLUME
21.02K
TURNOVER
--
52 WEEK HIGH
5.16
52 WEEK LOW
0.6015
MARKET CAP
13.51M
P/E (TTM)
-0.2112
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MTVA last week (0707-0711)?
Weekly Report · 1d ago
MetaVia Initiates Phase 1 Trial for Obesity Drug
TipRanks · 6d ago
MetaVia Doses First Patient In 48 Mg, MAD Cohort Of Phase 1 Clinical Trial Of DA-1726, OXM Analog Agonist That Functions As GLP1R And GCGR, For Treatment Of Obesity
Benzinga · 6d ago
Metavia Inc. Doses First Patient in 48 mg Cohort of Phase 1 Trial for Obesity Drug DA-1726, Top-Line Data Expected by End of 2025
Reuters · 6d ago
METAVIA INC - TOP-LINE DATA EXPECTED IN Q4 2025
Reuters · 6d ago
Weekly Report: what happened at MTVA last week (0630-0704)?
Weekly Report · 07/07 10:22
MetaVia registers 14.1M shares for resale
Seeking Alpha · 07/02 20:18
MetaVia files to sell 14.08M shares of common stock for holders
TipRanks · 07/02 20:10
More
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Webull offers MetaVia Inc stock information, including NASDAQ: MTVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTVA stock methods without spending real money on the virtual paper trading platform.